专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07202065B2 Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme 有权
标题翻译：活化凝血因子VII或其酶原的蛋白酶的稳定液体制剂
公开(公告)号：US07202065B2
公开(公告)日：2007-04-10
申请号：US10033777
申请日：2002-01-03
申请人： Jürgen Römisch , Annette Feussner , Christian Kannemeier , Hans-Arnold Stöhr
发明人： Jürgen Römisch , Annette Feussner , Christian Kannemeier , Hans-Arnold Stöhr
IPC分类号： C12N9/00
CPC分类号： A61K47/183 , A61K38/482
摘要： A stabilized liquid preparation of a protease which activates blood coagulation Factor VII or of its proenzyme is herein described. The preparation also contains one or more compounds selected from the group consisting of ornithine, diaminopimelic acid, agmatine, creatine, guanidinoacetic acid, acetylornithine, citrulline, arginoinosuccinic acid, tranexamic acid and epsilon-aminocaproic acid or their salts and has a pH of 2–8.
摘要翻译：本文描述了活化凝血因子VII或其酶原的蛋白酶的稳定化液体制剂。该制剂还含有一种或多种选自鸟氨酸，二氨基庚二酸，丁胺，肌酸，胍基乙酸，乙酰鸟氨酸，瓜氨酸，氨基琥珀酸，氨甲环酸和ε-氨基己酸或其盐的化合物，其pH为2- 8。

2. 发明授权

US06573056B2 Process for purifying factor VII and activated factor VII 有权
标题翻译：纯化因子VII和活化因子VII的方法
公开(公告)号：US06573056B2
公开(公告)日：2003-06-03
申请号：US09768294
申请日：2001-01-25
申请人： Jürgen Römisch , Hans-Arnold Stöhr , Annette Feussner
发明人： Jürgen Römisch , Hans-Arnold Stöhr , Annette Feussner
IPC分类号： G01N3353
CPC分类号： C12N9/6437 , C12Y304/21021
摘要： The invention relates to a process for purifying factor VII and/or activated factor VIIa (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin.
摘要翻译：本发明涉及通过结合固定化的可溶性凝血激酶原来纯化因子VII和/或活化因子VIIa（F VII / F VIIa）的方法。

3. 发明授权

US06911334B2 Protease for activating clotting factor VII 有权
标题翻译：用于激活凝血因子VII的蛋白酶
公开(公告)号：US06911334B2
公开(公告)日：2005-06-28
申请号：US10319592
申请日：2002-12-16
申请人： Jürgen Römisch , Annette Feussner , Hans-Arnold Stöhr
发明人： Jürgen Römisch , Annette Feussner , Hans-Arnold Stöhr
IPC分类号： A61K38/46 , A61K38/00 , A61K38/48 , A61L15/38 , C07K14/745 , C12N9/64 , C12Q1/56 , G01N33/53 , G01N33/86 , C12N9/50 , A07K14/00
CPC分类号： A61L15/38 , A61K38/00 , A61K38/57 , C07K14/745 , C12N9/6424 , C12Q1/56 , G01N33/86 , G01N2333/96447
摘要： A protease for activating the blood clotting factor VII is described, wherein the protease is inhibited by the presence of aprotinin and is increased in its activity by calcium ions and/or heparin or heparin-related substances, and wherein in SDS-PAGE, on subsequent staining in the non-reduced state, the protease has one or more brands in the molecular weight range from 50 to 75 kDa, and in the reduced state, the protease has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa. The proenzyme of this protease is also characterized. Further, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described.
摘要翻译：描述了用于激活血液凝固因子VII的蛋白酶，其中蛋白酶被抑肽酶抑制，并且其钙离子和/或肝素或肝素相关物质的活性增加，并且其中在SDS-PAGE中，随后在非还原状态下染色，蛋白酶在50至75kDa的分子量范围内具有一个或多个品牌，并且在还原状态下，蛋白酶具有在40至55kDa的条带和分子中的一个或多个条带重量范围为10至35kDa。该蛋白酶的酶还具有特征。此外，描述了获得该蛋白酶的方法及其在出血预防或止血中的用途。此外，描述了用于定性和定量检测激活凝血因子VII的蛋白酶的测试系统。

4. 发明授权

US06528299B1 Protease for activating clotting factor VII 有权
标题翻译：用于激活凝血因子VII的蛋白酶
公开(公告)号：US06528299B1
公开(公告)日：2003-03-04
申请号：US09295316
申请日：1999-04-21
申请人： Jürgen Römisch , Annette Feussner , Hans-Arnold Stöhr
发明人： Jürgen Römisch , Annette Feussner , Hans-Arnold Stöhr
IPC分类号： C12N950
CPC分类号： A61L15/38 , A61K38/00 , A61K38/57 , C07K14/745 , C12N9/6424 , C12Q1/56 , G01N33/86 , G01N2333/96447
摘要： A protease for activating the blood clotting factor VII, which is inhibited by the presence of aprotinin, is increased in its activity by calcium ions and/or heparin or heparin-related substances, and in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band in the molecular weight range between 60 and 65 kDa, which corresponds to a proenzyme. Pharmaceutical preparations containing the protease or its proenzyme are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin.
摘要翻译：通过钙离子和/或肝素或肝素相关物质活化通过抑肽酶抑制的血液凝固因子VII的蛋白酶的活性增加，并且在SDS-PAGE中，随后在非 - 还原状态包含分子量范围为50至75kDa的一个或多个条带; 并且在SDS-PAGE中，在随后的还原状态染色中，包含40至55kDa的条带，分子量范围为10至35kDa的一个或多个条带和分子量范围为60至65的条带 kDa，其对应于酶原。含有蛋白酶或其酶的药物制剂适用于预防和治疗出血事件，例如，在FVIII抑制剂的存在下，伤口愈合和用于治疗由含纤维蛋白的凝血酶引起的疾病。

5. 发明授权

US07879803B2 Methods of treatment involving the protease for activating clotting factor VII 有权
标题翻译：涉及蛋白酶激活凝血因子VII的治疗方法
公开(公告)号：US07879803B2
公开(公告)日：2011-02-01
申请号：US11984058
申请日：2007-11-13
申请人： Jürgen Römisch , Annette Feussner , Hans-Arnold Stöhr
发明人： Jürgen Römisch , Annette Feussner , Hans-Arnold Stöhr
IPC分类号： A61K38/00
CPC分类号： A61L15/38 , A61K38/00 , A61K38/57 , C07K14/745 , C12N9/6424 , C12Q1/56 , G01N33/86 , G01N2333/96447
摘要： This application describes methods of treatment involving a protease for activating the blood clotting factor VII, which (a) activates blood clotting factor VII, (b) is inhibited by the presence of aprotinin, (c) is increased in its activity by the presence of at least one of the following: calcium ions, heparin, or heparin related substances, and (d) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more bands in the molecular weight range from 50 to 75 kDa, and in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa, and a band, which corresponds to a proenzyme, in the molecular weight range from 60 to 65 kDa.
摘要翻译：本申请描述了涉及用于激活血液凝固因子VII的蛋白酶的治疗方法，其中（a）激活血液凝固因子VII，（b）被抑肽酶抑制，（c）通过存在抑制素而增加其活性以下中的至少一种：钙离子，肝素或肝素相关物质，和（d）在SDS-PAGE中，在未还原状态下随后的染色具有一个或多个分子量范围为50至75的条带 kDa，并且在还原状态下具有40至55kDa的条带和分子量范围为10至35kDa的一个或多个条带和对应于分子量范围为60至65的酶的条带 kDa。

6. 发明授权

US06479245B1 Monoclonal antibody which is specific for activated coagulation factor VII, and its use 有权
标题翻译：活化凝血因子VII特异的单克隆抗体及其用途
公开(公告)号：US06479245B1
公开(公告)日：2002-11-12
申请号：US09234504
申请日：1999-01-21
申请人： Jürgen Römisch , Wiegand Lang , Annette Feussner , Joachim Röder
发明人： Jürgen Römisch , Wiegand Lang , Annette Feussner , Joachim Röder
IPC分类号： G01N3353
CPC分类号： C12N9/6437 , A61K38/00 , C07K16/40 , C07K2317/24 , C12Y304/21021
摘要： A monoclonal antibody has been developed which only specifically binds activated factor VII, and not factor VII, and which does not bind to an activated factor VII which is complexed with antithrombin III. This monoclonal antibody is isolated from the hybridoma cell line DSM ACC 2332. It can be used for qualitatively and quantitatively detecting factor VIIa in body fluids, blood coagulation preparations or the intermediate stages in the production of these preparations, on cell surfaces or in tissues, and can also be used as a humanized monoclonal antibody in therapeutic preparations.
摘要翻译：已经开发了单克隆抗体，其仅特异性结合活化因子VII而不是因子VII，并且不结合与抗凝血酶III复合的活化因子VII。该单克隆抗体从杂交瘤细胞系DSM ACC 2332中分离出来。它可用于定性和定量检测体液，血液凝固制剂或这些制剂的生产中的中间阶段，细胞表面或组织中的VIIa因子，并且也可以用作治疗制剂中的人源化单克隆抗体。

7. 发明授权

US06906183B2 Process for the separation of glycosylated and nonglycosylated proteins 失效
标题翻译：分离糖基化和非糖基化蛋白的方法
公开(公告)号：US06906183B2
公开(公告)日：2005-06-14
申请号：US09459908
申请日：1999-12-14
申请人： Jürgen Römisch , Jörg Weisse , Harald Stauss , Annette Feussner
发明人： Jürgen Römisch , Jörg Weisse , Harald Stauss , Annette Feussner
IPC分类号： C12N15/09 , C07K1/14 , C07K1/22 , C07K14/76 , A23J1/00 , C07K1/00
CPC分类号： C07K1/22 , C07K14/76
摘要： A process for the partial or complete separation of glycosylated and nonglycosylated proteins is described, in which: a) a triazine dye immobilized on a matrix is incubated with a mixture of glycosylated and nonglycosylated proteins, b) the matrix is then washed to remove the unbound proteins, and c) the proteins are eluted by means of a stepwise or continuous increase in the ionic strength or in the pH, nonglycosylated proteins and proteins having an increasing degree of glycosylation being collected separately from one another in the eluate fractions obtained. By means of the use of this process it is possible, for example, to prepare a human albumin which is free of glycoside bonds and is expressed in yeast cells.
摘要翻译：描述了部分或完全分离糖基化和非糖基化蛋白质的方法，其中：a）固定在基质上的三嗪染料与糖基化和非糖基化蛋白质的混合物一起孵育，b）然后洗涤基质以除去未结合的蛋白质，以及c）蛋白质通过离子强度或pH的逐步或连续增加被洗脱，具有增加糖基化程度的非糖基化蛋白质和蛋白质在获得的洗脱液组分中彼此分开收集。通过使用该方法，例如可以制备不含糖苷键并在酵母细胞中表达的人白蛋白。

8. 发明授权

US06835817B2 Monoclonal antibody which is specific for activated coagulation factor VII, and its use 失效
标题翻译：活化凝血因子VII特异的单克隆抗体及其用途
公开(公告)号：US06835817B2
公开(公告)日：2004-12-28
申请号：US10226118
申请日：2002-08-23
申请人： Jürgen Römisch , Wiegand Lang , Annette Feussner , Joachim Röder
发明人： Jürgen Römisch , Wiegand Lang , Annette Feussner , Joachim Röder
IPC分类号： C07K1600
CPC分类号： C12N9/6437 , A61K38/00 , C07K16/40 , C07K2317/24 , C12Y304/21021
摘要： A monoclonal antibody has been developed which only specifically binds activated factor VII, and not factor VII, and which does not bind to an activated factor VII which is complexed with antithrombin III. This monoclonal antibody is isolated from the hybridoma cell line DSM ACC 2332. It can be used for qualitatively and quantitatively detecting factor VIIa in body fluids, blood coagulation preparations or the intermediate stages in the production of these preparations, on cell surfaces or in tissues, and can also be used as a humanized monoclonal antibody in therapeutic preparations.
摘要翻译：已经开发了单克隆抗体，其仅特异性结合活化因子VII而不是因子VII，并且不结合与抗凝血酶III复合的活化因子VII。该单克隆抗体从杂交瘤细胞系DSM ACC 2332中分离出来。它可用于定性和定量检测体液，血液凝固制剂或这些制剂的生产中的中间阶段，细胞表面或组织中的VIIa因子，并且也可以用作治疗制剂中的人源化单克隆抗体。

9. 发明申请

US20100330568A1 ASSAY AND METHOD FOR THE ASSESSMENT OF RESPONDERS AND NON-RESPONDERS TO NK CELL MODULATION BY IMMUNOGLOBULIN THERAPY 审中-公开
标题翻译：免疫球蛋白治疗对NK细胞调节的反应物和非对称性的评估和方法
公开(公告)号：US20100330568A1
公开(公告)日：2010-12-30
申请号：US12735313
申请日：2009-01-09
申请人： Stefan Meuer , Thomas Giese , Christian Jacobi , Jürgen Römisch , Stefan Haag
发明人： Stefan Meuer , Thomas Giese , Christian Jacobi , Jürgen Römisch , Stefan Haag
IPC分类号： C12Q1/68 , G01N33/68 , C12Q1/02
CPC分类号： G01N33/6854 , G01N33/5047
摘要： A method of determining a patient's susceptibility for NK cell modulation by immunoglobulins in response to a treatment of a disease or prophylaxis of a disease with immunoglobulins wherein a modulation of natural killer cells caused by said immunoglobulins is determined.
摘要翻译：确定患者对免疫球蛋白响应于疾病治疗或用免疫球蛋白预防疾病的NK细胞调节的敏感性的方法，其中确定由所述免疫球蛋白引起的天然杀伤细胞的调节。

10. 发明授权

US06242239B1 Process for separating HIV from a fluid 失效
标题翻译：从流体中分离HIV的方法
公开(公告)号：US06242239B1
公开(公告)日：2001-06-05
申请号：US09336675
申请日：1999-06-21
申请人： Albrecht Gröner , Jürgen Römisch
发明人： Albrecht Gröner , Jürgen Römisch
IPC分类号： C07K1481
CPC分类号： C12N7/00 , A61L2/0017 , A61L2/0082 , C12N2740/16051
摘要： A process for separating HIV from a fluid is described, in which the HIV is bound to a C1 esterase inhibitor immobilized on a support material. The process can be carried out both for the preparation of HIV-free blood donations and therapeutically for the reduction of the virus load in the blood by means of a blood lavage under the conditions of an extracorporeal blood circulation. The C1 esterase inhibitor can be bonded to a support material which is customary in affinity chromatography or to the fibers of a filter.
摘要翻译：描述了从流体中分离HIV的方法，其中HIV与固定在载体材料上的C1酯酶抑制剂结合。该过程可以用于制备无HIV血液捐赠，并且在体外血液循环的条件下通过血液灌洗在治疗上用于减少血液中的病毒载量。 C1酯酶抑制剂可以结合到通常在亲和层析中或过滤器的纤维上的载体材料。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式